期刊文献+

外周血肿瘤标志物对周围型肺癌切除术后复发转移的预测价值 被引量:3

The predictive value of peripheral blood tumor markers for recurrence and metastasis of peripheral lung cancer after resection
下载PDF
导出
摘要 目的 分析周围型肺癌患者外周血组织金属蛋白酶抑制剂1(TIMP-1)、细胞角蛋白-19片段(CYFRA21-1)、基质金属蛋白酶9(MMP-9)对术后复发转移预测价值。方法 我院收治的周围型肺癌且术后1年内复发患者77例为复发组,同期收治且术后1年内未复发周围型肺癌患者91例为非复发组,同期健康体检者50例为对照组。检测三组血清CYFRA21-1、MMP-9、TIMP-1水平。比较不同血清CYFRA21-1、MMP-9、TIMP-1水平患者术后复发率;分析术后复发转移影响因素。评估TIMP-1、CYFRA21-1、MMP-9对患者术后复发预测价值。结果 复发组吸烟史和III期比例多于非复发组(P<0.05)。复发组CYFRA21-1、MMP-9、TIMP-1水平高于对照组和非复发组(P<0.05)。MMP-9、TIMP-1、CYFRA21-1低表达组复发率低于高表达组(P<0.05)。CYFRA21-1、MMP-9和TIMP-1水平是术后复发的影响因素。血清CYFRA21-1、MMP-9、TIMP-1评估肺癌患者复发转移的AUC分别为0.782、0.806、0.829,联合预测的AUC为0.923。结论 术后复发患者血清CYFRA21-1、MMP-9、TIMP-1高表达,三者高表达患者术后复发率高,对患者术后复发有一定预测价值,是术后复发危险因素。 Objective To analyze the predictive value of tissue inhibitor of matrix metalloproteinases-1(TIMP-1), cytokeratin-19,fragment 21-1(CYFRA21-1) and matrix metalloproteinase-9(MMP-9) in peripheral blood for recurrence and metastasis in patients with peripheral lung cancer.Methods Seventy-seven patients with peripheral lung cancer with recurrence within 1 year after surgery in our hospital were enrolled as a recurrence group. Another 91 patients with peripheral lung cancer without recurrence within 1 year after surgery were enrolled as a non-recurrence group. At the same period, 50 healthy subjects were enrolled as a control group. The levels of serum CYFRA21-1, MMP-9 and TIMP-1 were detected. The postoperative recurrence rates in patients with different levels of serum CYFRA21-1, MMP-9 and TIMP-1 were compared. The influencing factors of postoperative recurrence and metastasis were analyzed. The predictive value of CYFRA21-1, MMP-9 and TIMP-1 for postoperative recurrence was evaluated.Results The proportions of patients with smoking history and TNM staging at stage III in the recurrence group were significantly higher than those in the non-recurrence group(P<0.05). The levels of serum CYFRA21-1, MMP-9 and TIMP-1 in the recurrence group were higher than those in the control group and the non-recurrence group(P<0.05). The recurrence rates in the low-expression of CYFRA21-1, MMP-9 and TIMP-1 groups were lower than those in the corresponding high-expression groups(P<0.05). CYFRA21-1, MMP-9 and TIMP-1 were influencing factors of postoperative recurrence of peripheral lung cancer. Areas under ROC curve(AUC) of serum CYFRA21-1, MMP-9, and TIMP-1 for evaluating recurrence and metastasis in lung cancer patients were 0.782, 0.806, and 0.829, and combined detection of the three indicators was 0.923.Conclusion The levels of serum CYFRA21-1, MMP-9 and TIMP-1 are up-regulated in patients with postoperative recurrence. The postoperative recurrence rate is higher in patients with high expressions of CYFRA21-1, MMP-9 and TIMP-1. These three indicators have a certain predictive value for postoperative recurrence. They are risk factors for postoperative recurrence.
作者 周宇 王志宏 段东奎 ZHOU Yu;WANG Zhi-hong;DUAN Dong-kui(Nanyang Central Hospital,Nanyang 473000,China)
出处 《实用医院临床杂志》 2022年第5期124-127,共4页 Practical Journal of Clinical Medicine
关键词 细胞角蛋白-19片段 基质金属蛋白酶9 组织金属蛋白酶抑制剂1 肺癌 复发 Cytokeratin-19 fragment 21-1 Matrix metalloproteinase-9 Tissue inhibitor of matrix metalloproteinases-1 Lung cancer Recurrence
  • 相关文献

参考文献18

二级参考文献138

  • 1王万里,郭淑利,王慧睿.微小RNA-92a靶向FHIT基因调控淋巴瘤细胞增殖及凋亡的机制研究[J].中华生物医学工程杂志,2019,25(2):177-182. 被引量:2
  • 2林昆,张国恺,朱碧柳,戴杰民.广东食管癌高低发区烟酒消费与食管癌的关系[J].疾病控制杂志,2006,10(1):5-7. 被引量:6
  • 3吴一龙,蒋国梁,廖美琳,周清华,陆舜,王绿化,张力,无.非小细胞肺癌孤立性转移处理共识[J].循证医学,2007,7(2):109-111. 被引量:22
  • 4Liu L, Liu B, Zhu LL, et al. Clinical significance of CYFRA21-1, Sec-Ag and telomerase activity in serum and pleural effusion of patients with squamous-ceU lung cancer [J].Bioanalysis, 2012, 4 (19) : 2367-2374.
  • 5Lee DS, Kim SJ, Kang JH, et al. Serum Carcinoembryonic Antigen Levels and the Risk of Whole-body Metastatic Potential in Advanced Non-small Cell Lung Cancer [J]. J Cancer, 2014, 5 (8) : 663-669.
  • 6Yang ZM, Ding XP, Pen L, et al. Analysis of CEA expressionand EGFR mutation status in non-small cell lung cancers [J]. Asian Pac J Cancer Prey, 2014,15 (8) :3451-3455.
  • 7Qin HF, Qu LL, Liu H, et al. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer [J]. Asian Pac J Cancer Prey, 2013,14(7) :4205-4208.
  • 8Ma S, Shen L, Qian N, et al. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited [J]. Cancer Biomark, 2011-2012(3-4) : 155-162.
  • 9Fiala O, Pesek M, Finek J, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib [J]. Anticancer Res, 2014,34(6) : 3205-3210.
  • 10Jung M, Kim SH, Hang S, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib [J ]. Yonsei Med J, 2012,53 (5) : 931-939.

共引文献498

同被引文献41

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部